Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk:: Results from the European prospective investigation into cancer and nutrition

被引：80

作者：

Allen, Naomi E. ^{[1
]}

Key, Timothy J.

Appleby, Paul N.

Travis, Ruth C.

Roddam, Andrew W.

Rinaldi, Sabina

Egevad, Lars

Rohrmann, Sabine

Linseisen, Jakob

Pischon, Tobias

Boeing, Heiner

Johnsen, Nina Fons

Tjonneland, Anne

Gronbaek, Henning

Overvad, Kim

Kiemeney, Lambartus

Bueno-de-Mesquita, H. Bas

Bingham, Sheila

Khaw, Kay Tee

Tumino, Rosario

Berrino, Franco

Mattiello, Amalia

Sacerdote, Carlotta

Palli, Domenico

Quiros, Jos Ramon

Ardanaz, Eva

Navarro, Carmen

Larranaga, Nerea

Gonzalez, Carlos

Sanchez, Maria-Jose

Trichopoulou, Antonia

Travezea, Cryssoula

Trichopoulos, Dimitrios

Jenab, Mazda

Ferrari, Pietro

Riboli, Elio

Kaaks, Rudolf

机构：

[1] Univ Oxford, Canc Res UK Epidemiol, Oxford OX3 7LF, England

[2] IARC, Lyon, France

[3] Deutsch Krebsforschungszentrum, Div Canc Epidemiol, D-6900 Heidelberg, Germany

[4] German Inst Human Nutr Potsdam Rehbrucke, Dept Epidemiol, Nuthetal, Germany

[5] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark

[6] Aarhus Univ Hosp, Med Dept 5, DK-8000 Aarhus, Denmark

[7] Aarhus Univ Hosp, Aalborg Hosp, Dept Clin Epidemiol, Aalborg, Denmark

[8] Univ Nijmegen, Med Ctr, Dept Epidemiol, Nijmegen, Netherlands

[9] Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands

[10] Natl Inst Publ Hlth & Environm, Ctr Nutr & Hlth, NL-3720 BA Bilthoven, Netherlands

[11] Univ Cambridge, MRC, Dunn Human Nutr Unit, Dept Publ Hlth & Primary Care, Cambridge, England

[12] Univ Cambridge, MRC, Ctr Nutr Epidemiol Canc Prevent & Survival, Dept Publ Hlth & Primary Care, Cambridge, England

[13] Univ Cambridge, Sch Clin Med, Addenbrookes Hosp, Clin Gerontol Unit, Cambridge, England

[14] Azienda Osped Civile MP Arezzo, Canc Registry, Ragusa, Italy

[15] Ist Nazl Tumori, Epidemiol Unit, I-20133 Milan, Italy

[16] Univ Naples Federico II, Dipartimento Med Clin & Sperimentale, Naples, Italy

[17] Ctr Canc Prevent Piemonte, Dept Biomed Sci & Human Oncol, Turin, Italy

[18] Sci Inst Tuscany, Ctr Study & Prevent Canc, Mol & Nutr Epidemiol Unit, Florence, Italy

[19] Publ Hlth & Hlth Planning Directorate, Asturias, Spain

[20] Publ Hlth Inst Navarra, Pamplona, Spain

[21] Murcia Hlth Council, Dept Epidemiol, Murcia, Spain

[22] Basque Govt, Publ Hlth Dept Gipuzkoa, San Sebastian, Spain

[23] Catalan Inst Oncol, Dept Epidemiol, Barcelona, Spain

[24] Escuela Andaluza Salud Publ, Granada, Spain

[25] Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-10679 Athens, Greece

[26] Hellenic Hlth Fdn, Athens, Greece

[27] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London, England

来源：

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2007年 / 16卷 / 06期

基金：

英国医学研究理事会; 英国惠康基金;

关键词：

D O I：

10.1158/1055-9965.EPI-06-1062

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer. Methods: We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression. Results: The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; P-trend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; P-trend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; P-trend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; P-trend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-l concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; P-trend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; P-trend = 0.11) for IGF-I adjusted for IGFBP-3. Conclusions: In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed.

引用

页码：1121 / 1127

页数：7

共 32 条

[11] INSULIN-LIKE GROWTH FACTOR-I - ACTION AND RECEPTOR CHARACTERIZATION IN HUMAN PROSTATE-CANCER CELL-LINES [J].

IWAMURA, M ;

SLUSS, PM ;

CASAMENTO, JB ;

COCKETT, ATK .

PROSTATE, 1993, 22 (03) :243-252

[12] Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer:: Results of a case-control study involving 201 patients within a population-based screening with a 4-year interval [J].

Janssen, JAMJL ;

Wildhagen, MF ;

Ito, K ;

Blijenberg, BG ;

van Schaik, RHN ;

Roobol, MJ ;

Pols, HAP ;

Lamberts, SWJ ;

Schröder, FH .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (09) :4391-4396

[13] INSULIN-LIKE GROWTH-FACTORS AND THEIR BINDING-PROTEINS - BIOLOGICAL ACTIONS [J].

JONES, JI ;

CLEMMONS, DR .

ENDOCRINE REVIEWS, 1995, 16 (01) :3-34

[14] Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women [J].

Kaaks, R ;

Toniolo, P ;

Akhmedkhanov, A ;

Lukanova, A ;

Biessy, C ;

Dechaud, H ;

Rinaldi, S ;

Zeleniuch-Jacquotte, A ;

Shore, RE ;

Riboli, E .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (19) :1592-1600

[15]

Kaaks R, 2001, CANCER EPIDEM BIOMAR, V10, P1103

[16]

Lacey JV, 2001, CANCER EPIDEM BIOMAR, V10, P1101

[17] Prediagnostic levels of C-peptide, IGF-I, IGFBP-1,-2 and-3 [J].

Lukanova, A ;

Zeleniuch-Jacquotte, A ;

Lundin, E ;

Michel, A ;

Arslan, AA ;

Rinaldi, S ;

Muti, P ;

Lenner, P ;

Koenig, KL ;

Biessy, C ;

Krogh, V ;

Riboli, E ;

Shore, RE ;

Stattin, P ;

Berrino, F ;

Hallmans, C ;

Toniolo, P ;

Kaaks, R .

INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (02) :262-268

[18] A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial [J].

Meyer, F ;

Galan, P ;

Douville, P ;

Bairati, I ;

Kegle, P ;

Bertrais, S ;

Czernichow, S ;

Hercberg, S .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (09) :2269-2272

[19] Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies [J].

Montironi, R ;

Mazzuccheli, R ;

Scarpelli, M ;

Lopez-Beltran, A ;

Fellegara, G ;

Algaba, F .

BJU INTERNATIONAL, 2005, 95 (08) :1146-1152

[20] Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies [J].

Morris, J. K. ;

George, L. M. ;

Wu, T. ;

Wald, N. J. .

BRITISH JOURNAL OF CANCER, 2006, 95 (01) :112-117

← 1 2 3 4 →